Autobahn Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.autobahntx.com
Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Autobahn Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06869187
- Locations
- 🇺🇸
Autobahn Site #201, Cromwell, Connecticut, United States
🇺🇸Autobahn Site #208, Cherry Hill, New Jersey, United States
🇺🇸Autobahn Site #205, Marlton, New Jersey, United States
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-06-20
- Lead Sponsor
- Autobahn Therapeutics, Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT06633016
- Locations
- 🇺🇸
Autobahn Site #131, Birmingham, Alabama, United States
🇺🇸Autobahn Site #132, Chandler, Arizona, United States
🇺🇸Autobahn Site #116, Phoenix, Arizona, United States
SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Autobahn Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05528315
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
News
No news found